Proteolytic Imbalance in Depression as Potential Pathological Trait of Diseases
Journal: International Journal of Science and Research (IJSR) (Vol.3, No. 10)Publication Date: 2014-10-05
Authors : Fakhra Amin; Bilqees Bano;
Page : 972-976
Keywords : Haloperidol; Cystatin; Antidepressant; Neurotransmitter; Purification of Buffalo Brain Cystatin; Thiol Proteinase Inhibitors; depression schizophrenia;
Abstract
Cystatins are the thiol Proteinase inhibitors, present ubiquitously in mammalian body. They prevent unwanted proteolysis and play important role in several diseases. Regulation of cysteine Proteinase and their inhibitors is of utmost importance in diseases like Alzheimer, amlyoid angiopathy and other neurodegenerative disease. Haloperidol is an antipsychotic drug used in the treatment of schizophrenia. In this paper interaction of brain cystatin ( BC) with haloperidol has been studied by U. V absorption and fluorescence spectroscopy to explore the drug induced changes in functional and structural integrity of the brain cystatin. The fluorescence quenching data analysed by stern vomer analyses indicated the presence of static component in the quenching mechanism. The thermodynamic parameters G0 (Free energy change) found to be -39.377 KJ/mol revealed that both hydrogen bonds and hydrophobic interactions played a major role in the binding of Haloperidol with BC. This binding leads to decrease in the activity of cystatin showing its involvement in protease -antiprotease imbalance It may also be taken as the side effect of the drug haloperidol, such studies may be used as a tool for drug designing.
Other Latest Articles
- A Novel Method Defense against IP Spoofing Using Packet Filtering and Marking
- Fibrinolytic Serine Protease Isolated from Earthworm Lampito mauritii
- A Study to Assess the Knowledge of Primary School Children Regarding Sources, Deficiencies and Importance of Vitamin - A in Selected School of Vadagaon Haveli
- Pteridophytic Composition in Banajalaya Forest Region, Karnataka, South India
- Efficacy of Stabilization Splint in Management of Myogenous Temporomandibular Disorders
Last modified: 2021-06-30 21:10:56